布地奈德缓释胶囊导致的不良反应怎么治疗？

Introduction: Budesonide sustained-release capsules contain the active substance budesonide, a corticosteroid drug that mainly acts locally on the intestine to reduce inflammation associated with primary immunoglobulin A (IgA) nephropathy. Budesonide extended-release capsules are indicated for the treatment of primary IgA nephropathy in adults 18 years of age or older.

Adverse reactions caused by budesonide sustained-release capsules

Adverse reactions are usually mild and controllable, and mainly include acne, hypertension, peripheral edema, facial edema, indigestion, muscle spasm, headache, etc. They are generally mild to moderate, reversible, and well tolerated.

How to treat adverse reactions caused by budesonide sustained-release capsules

1. Hypertension: The dose may need to be adjusted or antihypertensive drugs may be used. At the same time, patients are advised to monitor their blood pressure and adjust their lifestyle under the guidance of a doctor, such as reducing salt intake and increasing moderate exercise.

2. Muscle spasm: It can be relieved by supplementing foods or drugs containing potassium and magnesium, while maintaining appropriate water intake.

3. Facial and peripheral edema: It can be relieved by limiting salt intake, elevating the affected limb, and using diuretics.

4. Acne: It is recommended that patients use mild skin care products, avoid using irritating skin care products or cosmetics, and use appropriate topical treatments under the guidance of a doctor.

5. Fatigue: Ensure adequate rest and sleep. If necessary, consult your doctor whether you need to adjust drug dosage or use other drugs to increase energy levels.

Patients should inform their doctor immediately after experiencing side effects so that the doctor can evaluate the situation and provide appropriate treatment recommendations.

Dosage and usage of budesonide sustained-release capsules

Budesonide sustained-release capsules (Kinpeygo) are 4 mg sustained-release hard capsules. The recommended dosage is 16 mg (4 capsules) once a day, taken orally in the morning, at least 1 hour before meals, and continued for 9 months. Treatment should be discontinued gradually, with the dose reduced to 8 mg once daily over 2 weeks, then further reduced to 4 mg once daily over a further 2 weeks, and then discontinued completely. If a patient forgets to take a budesonide extended-release capsule, the patient should take it as usual the next morning and should not double the daily dose to make up for the missed dose.

When discontinuing or reducing medication, patients should proceed gradually under the guidance of a doctor and should not stop medication or change the dose on their own to avoid worsening of symptoms.

It should be noted that the safety and effectiveness of budesonide extended-release capsules in patients with hepatic insufficiency have not yet been studied, and budesonide extended-release capsules are contraindicated in patients with severe hepatic insufficiency (Child-Pugh class C).